Buscopan 100ml

Composition :
N-butylscopolamine bromide (active substance): 4.00 mg
Metamizole sodium (active substance): 500.00 mg
Phenol (preservative): 5 mg

Characteristics
Buscopan® compositum contains the antispasmodic N-butylscopolamine bromide and the non-steroidal anti-inflammatory drug Metamizole (NSAIDs). Buscopan® compositum has an antispasmodic effect on the gastrointestinal tract and genitourinary system. In addition,
N-butylscopolamine bromide
N-butylscopolamine bromide is a quaternary ammonium derivative of scopolamine. This compound is an antagonist of the activity of acetylcholine on M-cholinergic receptors and also has some activity on nicotinic receptors. Its pharmacological properties are similar to the main representative of this class of drugs, atropine (such as antispasmodic properties, increased heart rate, and suppression of salivary and lacrimal secretions).
After parenteral administration, N-butylscopolamine bromide is mainly excreted in the urine (about 54%).
Metamizol
Metamizole inflammatory, analgesic and antipyretic action. The mechanism of its action, like other NSAIDs, is associated with the suppression of prostaglandin synthesis. In addition, it is an antagonist of bradykinin and histamine. After intravenous administration, excretion occurs mainly in the urine (50 – 70% depending on the type of animal).

Indications for
Horses:
Buscopan® compositum is indicated for the treatment of abdominal pain associated with spastic colic. Buscopan® compositum does not mask the symptoms in the case of surgical colic and does not cause intestinal paralysis.

Calves:
Buscopan® compositum is used in the treatment of calf diarrhea, it reduces pain and normalizes bowel function by reducing motility.

Contraindications:
None

Dosage and Administration
Adverse Effects (Frequency and Severity):
Horses may experience a slight and short-term increase in heart rate due to the parasympathetic activity of N-butylscopolamine bromide.

Special precautions:
None.

Use during pregnancy and lactation:
Laboratory studies in rats and rabbits have shown no obvious teratogenic effects. The drug can be used during pregnancy in normal doses.

Interaction with other medicinal products:
The concomitant use of other anticholinergic and analgesic agents can potentiate the effect of N-butylscopolamine bromide or metamizole. Although specific interactions have not been described, administration of other anticholinergic drugs is contraindicated.

Doses and routes of administration:
Horses:
Buscopan® compositum is prescribed in a single dose of 0.2 mg N-butylscopolamine bromide and 25 mg metamizole / kg body weight. This corresponds to 5 ml injection / 100 kg body weight intravenously.
After an intravenous injection of Buscopan® compositum, the antispasmodic effect occurs 2-5 minutes after administration and lasts for 4-6 hours. A single injection is usually sufficient to improve and reduce spasms and pain significantly. If necessary, Buscopan® compositum can be re-administered after 4-6 hours.

Calves:
Buscopan® compositum is administered at a dose of 0.4 mg N-butylscopolamine bromide and 50 mg metamizole/kg body weight at 12-hour intervals for a maximum of three days by intravenous or intramuscular injection. A single dose corresponds to 1 ml of solution for injection / 10 kg of body weight intravenously.

Overdose:
The toxicity of both components is very low. In a toxicity study in rats, nonspecific symptoms such as ataxia, mydriasis, tachycardia, prostration, convulsions, coma, and respiratory symptoms were identified.

Antidotes : Physostigmine for N-butylscopolamine bromide. There are no specific antidotes for metamizole. In case of overdose, symptomatic therapy is necessary.

Special warnings for each animal species:
No

Waiting period:
Horses: meat 9 days
Calves: meat 9 days

Special precautions for personnel directly working with the drug:
No

Incompatibility:
Not identified

Shelf life:
Unused bottle: 4 years
After first use: 6 months

Storage conditions:
Store below 30 ° C.